TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22220458

Group type: EXPERIMENTAL
Intervention: Pseudoexfoliative glaucoma
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Open angle glaucoma
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 129
Study: 18302020

Group type: EXPERIMENTAL
Intervention: Doxorubicin, cyclophosphamide, and docetaxel
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 708
Study: 17045903

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus training in physical counterpressure maneuvers (PCM)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Standardized conventional therapy alone
Number of subjects: 223
Study: 15613917

Group type: EXPERIMENTAL
Intervention: 75 g glucose
Number of subjects: 40

Group type: COMPARATOR
Intervention: 250 mg aspartame (control test)
Number of subjects: 40
Study: 10775738

Group type: EXPERIMENTAL
Intervention: 0.25 mg oral micronized 17beta‐E2
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: 0.5 mg oral micronized 17beta‐E2
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: 1 mg oral micronized 17beta‐E2
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: 2 mg oral micronized 17beta‐E2
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study: 9369050

Group type: EXPERIMENTAL
Intervention: Midazolam 3 mg i.m.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Clonidine 0.15 mg orally
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (Atropine 0.5 mg i.m.)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg i.m.
Number of subjects: 100
Study: 7690689

Group type: EXPERIMENTAL
Intervention: Pentastarch
Number of subjects: 41

Group type: COMPARATOR
Intervention: Ringer's lactate
Number of subjects: 41
Study: 3755561

Group type: EXPERIMENTAL
Intervention: 3 ml 0.5% hyperbaric tetracaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3 ml 0.5% hyperbaric bupivacaine
Number of subjects: 40
Study: 29864467

Group type: EXPERIMENTAL
Intervention: 40% hydrogen peroxide topical solution (HP40)
Number of subjects: 937

Group type: COMPARATOR
Intervention: vehicle (control)
Number of subjects: 937
Study: 26569059

Group type: EXPERIMENTAL
Intervention: Weekly methotrexate (MTX)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Dactinomycin
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Combined predictive groups from both arms
Number of subjects: 210
Study: 23981346

Group type: EXPERIMENTAL
Intervention: 130% of Pmax
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All loading protocols
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (without extra load)
Number of subjects: 12
Study: 22789134

Group type: EXPERIMENTAL
Intervention: 240 mg of pumactant
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo (carbon dioxide)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both groups (pumactant and placebo)
Number of subjects: 134
Study: 20561836

Group type: EXPERIMENTAL
Intervention: Program to Reduce Idiopathic Pulmonary Fibrosis Symptoms and Improve Management (6-week program)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 42
Study: 18756871

Group type: EXPERIMENTAL
Intervention: Ilio-inguinal blockade before surgical incision
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Local infiltration after closing the aponeurosis
Number of subjects: 60

Group type: COMPARATOR
Intervention: No local anesthetic infiltration (Control group III)
Number of subjects: 60
Study: 15756212

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 1 year
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 1 year followed by a second year of GH
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no GH for 1 year)
Number of subjects: 18
Study: 14620312

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 50
Study: 10500313

Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg/q12hr)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Unfractionated heparin (target aPTT: 55‐85 sec)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 174
Study: 8926771

Group type: EXPERIMENTAL
Intervention: HPV-infected women
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Progression of cervical lesions
Number of subjects: 528
Study: 1825737

Group type: EXPERIMENTAL
Intervention: Ketoconazole (600 mg/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 6361991

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusion
Number of subjects: 39

Group type: COMPARATOR
Intervention: No granulocyte transfusion (Control)
Number of subjects: 39
Study: 31138501

Group type: EXPERIMENTAL
Intervention: Standard femoral components
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Narrow femoral components
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: All systems
Number of subjects: 271
Study: 28049010

Group type: EXPERIMENTAL
Intervention: 2-hour bladder health class
Number of subjects: 647

Group type: COMPARATOR
Intervention: 20-minute abbreviated class video
Number of subjects: 647
Study: 24963912

Group type: EXPERIMENTAL
Intervention: ARME appliance
Number of subjects: 21
Study: 24668250

Group type: EXPERIMENTAL
Intervention: 0.5 Gy single dose
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: 1.0 Gy single dose
Number of subjects: 457
Study: 22926599

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) 0.5 mg/kg per day for 1 week, followed by 1.2 mg/kg per day for 7 weeks
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 19398192

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 400
Study: 16860259

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Sulfonylurea + Pioglitazone (SU + PIO)
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Metformin + Pioglitazone (MET + PIO)
Number of subjects: 891

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 891
Study: 15113713

Group type: EXPERIMENTAL
Intervention: DHA supplementation (2.8 g DHA/d)
Number of subjects: 32
Study: 11355946

Group type: EXPERIMENTAL
Intervention: Standard-dose FEC (5 adjuvant courses of 5-FU, epirubicin, and cyclophosphamide)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with PBSCT (4 x FEC followed by high-dose cyclophosphamide, thiotepa, carboplatin, and autologous PBSCT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Both standard-dose and high-dose chemotherapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Individual patients post-treatment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Telomerase activity
Number of subjects: 33
Study: 9120586

Group type: EXPERIMENTAL
Intervention: Unperturbed trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perturbed trials
Number of subjects: 0
Study: 8172356

Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT) with a purified standardized preparation of Dermatophagoides farinae for 12 months
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Open control group
Number of subjects: 31
Study: 2971185

Group type: EXPERIMENTAL
Intervention: RU 41740 (two tablets per day for one week during the first month and one tablet per day for one week during the second and third months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31885114

Group type: EXPERIMENTAL
Intervention: Computerized simulations embedded in pedagogically supportive activities (n = 40)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Routine face-to-face follow-up (Control group, n = 45)
Number of subjects: 85
Study: 31230495

Group type: EXPERIMENTAL
Intervention: EnHAp (nanohydroxyapatite synthesized from eggshell waste)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Colgate Sensitive
Number of subjects: 25

Group type: COMPARATOR
Intervention: Eggshell powder alone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Calcined eggshell powder
Number of subjects: 25

Group type: COMPARATOR
Intervention: Calcium dihydrogen phosphate
Number of subjects: 25
Study: 28674113

Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium animalis subsp lactis and Lactobacillus rhamnosus)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 26461100

Group type: EXPERIMENTAL
Intervention: Counselor‐Assisted Problem‐Solving (CAPS)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Internet resource comparison (IRC)
Number of subjects: 132
Study: 24315255

Group type: EXPERIMENTAL
Intervention: Active CES device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone (UC)
Number of subjects: 0
Study: 21715517

Group type: EXPERIMENTAL
Intervention: Enalapril or Losartan
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 17980009

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 22
Study: 16516598

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional treatment for heart failure
Number of subjects: 74
Study: 15281476

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (Pulmicort Respules)
Number of subjects: 2356

Group type: COMPARATOR
Intervention: Reference treatments
Number of subjects: 2356
Study: 12374901

Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg)
Number of subjects: 345
Study: 9818697

Group type: EXPERIMENTAL
Intervention: Once daily granisetron (1 mg i.v.) with dexamethasone (12 mg i.v.)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Twice daily granisetron (1 mg i.v.) with dexamethasone (12 mg i.v.)
Number of subjects: 70
Study: 7536271

Group type: COMPARATOR
Intervention: 5-fluorouracil alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil plus alpha-interferon
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil alone and with alpha-interferon
Number of subjects: 50
Study: 2527239

Group type: EXPERIMENTAL
Intervention: Farlutal (500 mg MPA tablets, twice daily for 20 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clinovir (500 mg MPA tablets, twice daily for 20 days)
Number of subjects: 16
Study: 4624595

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate administered 20 minutes before exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate administered immediately before exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate administered at the end of exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment (placebo)
Number of subjects: 10
Study: 30352271

Group type: EXPERIMENTAL
Intervention: PRECISE reporting workflow
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Osirix®
Number of subjects: 20
Study: 27387494

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Postural correction exercises (PCE)
Number of subjects: 46
Study: 25928870

Group type: EXPERIMENTAL
Intervention: Slow cortical potential (SCP) feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonspecific biofeedback treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 24298764

Group type: EXPERIMENTAL
Intervention: Bloodletting therapy at Jing‐well points
Number of subjects: 90

Group type: COMPARATOR
Intervention: Semen coicis preparation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Comprehensive therapy (bloodletting therapy and semen coicis preparation)
Number of subjects: 90
Study: 22184553

Group type: EXPERIMENTAL
Intervention: Deteriorating patient-based simulation (DPS)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standardized patients (SPs)
Number of subjects: 72
Study: 19253793

Group type: EXPERIMENTAL
Intervention: Immunonutrient containing enteral formula (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard enteral formula (group B)
Number of subjects: 40
Study: 16685008

Group type: EXPERIMENTAL
Intervention: Active heat exchanger mask
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo mask
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Heat exchanger mask
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Albuterol pretreatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Unprotected exercise
Number of subjects: 15
Study: 14993633

Group type: EXPERIMENTAL
Intervention: ROM (rifampin 600 mg, ofloxacin 400 mg, minocycline 100 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: MDT (rifampin 600 mg, clofazimine 300 mg, dapsone 100 mg, clofazimine 50 mg)
Number of subjects: 21
Study: 11485587

Group type: EXPERIMENTAL
Intervention: Anti-tubercular treatment
Number of subjects: 1343

Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 1343
Study: 9230332

Group type: EXPERIMENTAL
Intervention: alpha(2a)-interferon (3 mU/m2)
Number of subjects: 10
Study: 7954998

Group type: EXPERIMENTAL
Intervention: Standard block level (T10 or higher)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intermediate block level (L1 or T12)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low block level (L3 or lower)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low block level (inadequate block)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low block level (adequate block)
Number of subjects: 23
Study: 3825981

Group type: EXPERIMENTAL
Intervention: Obese women (pooled)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lean women
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Obese women (AOO and COO)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fat-free mass (FFM)
Number of subjects: 24
Study: 30484757

Group type: EXPERIMENTAL
Intervention: Maternal protein intake in early pregnancy (g/d per kg)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Maternal protein intake from 6 months to 5 years (g/d per kg)
Number of subjects: 570
Study: 28806537

Group type: EXPERIMENTAL
Intervention: Oral hydration (2000 ml of water)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control (no more than 100 ml of water)
Number of subjects: 164
Study: 26618557

Group type: EXPERIMENTAL
Intervention: Chitosan-coated garment
Number of subjects: 78

Group type: COMPARATOR
Intervention: Uncoated cotton garment (Control)
Number of subjects: 78
Study: 24042189

Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy (CSP)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cold forceps polypectomy (CFP)
Number of subjects: 54
Study: 21441125

Group type: EXPERIMENTAL
Intervention: Qa <650 ml/min in distal fistulae
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Positive PE and Qa <900 ml/min in proximal fistulae
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: PE and VAPR >0.5 in proximal fistulae
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Tailored screening approach
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Bedside screening program with ≥85% accuracy
Number of subjects: 119
Study: 18568520

Group type: EXPERIMENTAL
Intervention: N(2)O inhalation (10 breaths of 50% N(2)O/50% O(2))
Number of subjects: 90

Group type: COMPARATOR
Intervention: Room air inhalation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Local anesthesia only
Number of subjects: 90
Study: 17205818

Group type: EXPERIMENTAL
Intervention: Huashi Decoction (HD)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nucleotide analogies (Control)
Number of subjects: 70
Study: 12975669

Group type: EXPERIMENTAL
Intervention: gemcitabine/5‐fluorouracil (5FU)/leucovorin combination
Number of subjects: 34

Group type: COMPARATOR
Intervention: gemcitabine/cisplatin
Number of subjects: 34
Study: 11094000

Group type: COMPARATOR
Intervention: 10 mg of isobaric bupivacaine (0.2%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 15 mg of isobaric ropivacaine (0.3%)
Number of subjects: 100
Study: 8826511

Group type: EXPERIMENTAL
Intervention: Marital conflict/stress in chronic pain couples
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Punitive spouse behaviors
Number of subjects: 61
Study: 1595337

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine in combination with rectally administered naproxen 1000 mg/24 h
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine in combination with paracetamol 4000 mg/24 h
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine as a sole agent
Number of subjects: 125
Study: 6362760

Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31464192

Group type: EXPERIMENTAL
Intervention: Receipt of weekly recommendations
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Coaching
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Coached treatment
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Receiving recommendations
Number of subjects: 301
Study: 29712507

Group type: EXPERIMENTAL
Intervention: Sulodexide
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 27379182

Group type: EXPERIMENTAL
Intervention: Parent mentor intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Community health worker comparison
Number of subjects: 60
Study: 23917458

Group type: EXPERIMENTAL
Intervention: Tranexamic acid administered in 2 doses (1 hour preoperatively and 6 hours postoperatively)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 99
Study: 22464576

Group type: EXPERIMENTAL
Intervention: Conventional treatment (aspirin + low molecular weight heparin)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Combination of conventional treatment and clopidogrel
Number of subjects: 110

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ischemic cardiomyopathy (ICM) group
Number of subjects: 110
Study: 20044534

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target systolic BP 140 mmHg)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Standard guideline-based management of BP (target systolic BP 180 mmHg)
Number of subjects: 404
Study: 18327838

Group type: EXPERIMENTAL
Intervention: Pharmacological agents for inducing hyperaemia during coronary physiology studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary pressure wire studies
Number of subjects: 0
Study: 15899049

Group type: EXPERIMENTAL
Intervention: Risedronate 15 mg
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Risedronate (both doses)
Number of subjects: 284
Study: 12356708

Group type: EXPERIMENTAL
Intervention: Educational outreach visit
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuing professional education session
Number of subjects: 60

Group type: COMPARATOR
Intervention: Postal dissemination of evidence-based guideline (control)
Number of subjects: 60
Study: 11730758

Group type: COMPARATOR
Intervention: Intrauterine insemination (IUI)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Fallopian sperm perfusion (FSP)
Number of subjects: 132
Study: 9432085

Group type: EXPERIMENTAL
Intervention: 1-2 sessions/wk plus a 240 kcal caloric restriction (1-2SW, N = 9)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 3-4 sessions/wk without caloric restriction (3-4SW, N = 9)
Number of subjects: 26

Group type: COMPARATOR
Intervention: nonexercising control (C, N = 8)
Number of subjects: 26
Study: 8392175

Group type: EXPERIMENTAL
Intervention: Nutrition intervention aimed at promoting low-fat, high-fiber eating
Number of subjects: 652
Study: 3749616

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of salbutamol and beclomethasone dipropionate from a combination inhaler
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sequential administration of salbutamol and beclomethasone dipropionate from separate inhalers with an interval of 10 min
Number of subjects: 40
Study: 29268667

Group type: EXPERIMENTAL
Intervention: Standard care plus regular visits from a therapy dog
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 106
Study: 27442086

Group type: EXPERIMENTAL
Intervention: TRP mouthwash
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) mouthwash
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 90
Study: 26206854

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO) at listing
Number of subjects: 203

Group type: COMPARATOR
Intervention: Ventricular assist device at listing
Number of subjects: 203

Group type: COMPARATOR
Intervention: Not on ECMO or ventricular assist device at listing
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Transplantation from ECMO
Number of subjects: 203

Group type: COMPARATOR
Intervention: Transplantation from ventricular assist device
Number of subjects: 203

Group type: COMPARATOR
Intervention: Transplantation not on ECMO/ventricular assist device
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Transplantation from ECMO at age <1 year
Number of subjects: 203
Study: 23989837

Group type: EXPERIMENTAL
Intervention: Resin infiltration treatment for WSLs
Number of subjects: 0
Study: 21965636

Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/day
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Pregabalin (all doses)
Number of subjects: 747

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 747